Introduction
It has been known for many years thal de-energized mitochondria behave as perfect osmometers; as the osmolarity of the medium is altere'd, the matrix volume changes to equilibrate the osmotic pressure across the inner membrane [ 11. Indeed, the folding of the inner membrane into cristae allows mitochondria to swell to many times their original volume without rupturing. Under physiological conditions, however, mitochondria maintain their matrix volume within narrow limits through the operation of volume regulatory mechanisms that move K + and compensating anions in or out of the mitochondria. Research carried out in this laboratory during the past ten years has indicated that hormones acting on the cell surface are able to attenuate this regulatory mechanism and so cause small ( 10-3OYo) increases in the mitochondrial volume which have profound effects on mitochondrial metabolism. I have proposed that, in the liver, such volume-mediated changes in mitochondrial metabolism play a critical role in the stimulation of respiration, nitrogen metabolism and gluconeogenesis by hormones such as glucagon and adrenaline. This article provides a brief review of the work supporting this assertion and considers how it may relate to the current interest in the effect of cell volume on the regulation of metabolism. For more detailed reviews, the reader is directed elsewhere [ 1 , q .
Mechanisms involved in the regulation of mitochondrial matrix volume
It is generally agreed that mitochondria regulate their matrix volume through the movement across Abbreviations used: CoA, coenzyme A; DCMU, 3-(3,4-dichloropheny1)-1,l-dimethylurea. the inner membrane of K + and a compensating anion such as phosphate. K + enters the mitochondria through an electrogenic K + channel which is driven by the membrane potential and is pumped out again by a proton-linked antiporter [3,4]. The balance between the activities of these two transporters regulates the K + content of the matrix and hence its volume. When the matrix volume is increased by hypo-osmotic treatment or the addition of the K + ionophore valinomycin, a compensatory decrease in matrix volume is induced by activation of the antiporter. It has been suggested that this effect is mediated by a decrease in matrix [Mg2+], which acts as an inhibitor of the carrier [4, 5] . Rut others have pointed out that the decrease in [Mg"] that occurs on swelling is unlikely to be large enough to have the desired effect [6]. Furthermore, the K+-entry mechanism is also inhibited by Mg" on both sides of the membrane [7, 8] . Thus other factors, such as changes in pII or membrane stretch, may be important in the volume-mediated regulation of the antiporter [2, 9] . In recent years, the identity of the antiporter has been established as an 82 kI)a protein which has been purified and reconstituted into liposomes. In contrast, the identity of the K'-influx mechanism remains uncertain. It has been known for some time that K' influx is inhibited by adenine nucleotides, and an involvement of the adenine nucleotide translocase has been suggested by us and others [1, 3, 8, 10, 11] . More recently, patch clamping of mitochondria has suggested the presence of a sulphonylurea-sensitive potassium channel in the inner mitochondrial membrane [IZ] . 
Hormones can increase the mitochondrial matrix volume of hepatocytes
In the late 70s and early 80s, there was substiintial interest in how hormones might regulate mitoc hondrial function in the liver (see [15] ). Although i.: was well established that liver mitochondria isolated from rats treated with glucagon showed stimulation of many of their metabolic pathways, there was dispute as to whether such effects occurred in vivo. T o investigate this, we studied the mitochondria1 respiratory chain within intact hepatocytes using spectrophotometric techniques. During the course of these studies, we became aware of a hormoneinduced decrease in light scattering of cells treated with glucagon, phenylephrine or vasopressin. !Similar responses could be mimicked by low doses of the Kf ionophore valinomycin and were reininiscent of the light-scattering changes seen when mitochondria are swollen. Thus we began to investigate whether we might be observing an increase in mitochondrial volume in situ [ 161. W e were able to demonstrate that changing the cell volume by hyperosmotic stress had little effect on the lightscattering response (measured as AAS2") and that hormones did not change the cell volume under our incubation conditions. Thus cell volume changes could not account for the decrease in light scattering. In order to measure the mitochondrial volume more directly, we devised two techniques. First, a rapid cellular disruption technique in the presence of 'H,O and ['4C ]sucrose followed by mitochondrial sedimentation was used to measure the matrix volume within 1-2 min of breaking the cell by gentle sonication. Second, the use of 'H20 and ["C]mannitol (which penetrates the plasma membrane but not the mitochondrial inner membrane) followed by sedimentation of the cells and assay of jH and ["C] enabled the matrix volume to be measured without cell disruption [16] . Both the radioactive and the light-scattering techniques gave similar results for the hormone-induced increase in matrix volume, as shown in Figure 1 . The effects were smallest with glucagon and phenylephrine, greater with vasopressin and largest when phenylephrine or vasopressin were added in the presence of glucagon. Responses could also be induced by concentrations of valinomycin known to stimulate The effects of hormones and valinomycin on the mitochondrial matrix volume of hepatocytes
The data are taken from [ 16,171, [20, 21] , we have been unable to find evidence for it in liver or heart mitochondria [22] . Rather, our data support the proposal that PP, synthesis is a very minor side reaction of the normal F,-ATPase [23].
The mechanism by which PP, activates K + entry into mitochondria is uncertain. PP, is known to be a substrate for the adenine nucleotide translocase, and we have suggested that when matrix [PP,] is increased, it may displace some adenine nucleotides from their binding sites on the translocase and induce a K + -permeable conformation [ 8, 241 . Rut the recent evidence of an ATP-regulated K' channel that is inhibited by glibencamide [12, 13] suggests that PP, may interact with the ATP-binding site of this channel. W e are currently investigating whether glibencamide can decrease the mitochondrial matrix volume in uitro or in situ, or attenuate the Caz+-and PP,-dependent volume changes, but so far we have been unable to demonstrate any significant effects.
The effects of matrix volume on mitochondrial function
Work from this and other laboratories has demonstrated that changes in mitochondrial matrix volume over the physiological range (1.0-IS pVmg protein) stimulate many aspects of mitochondrial metabolism [ 1,2,2.5]. Figure 2 summarizes these data. The oxidation of fatty acids is greatly stimulated, by an increase in electron transfer between flavoprotein and ubiquinone [26, 27] , and the oxidations of NADH, succinate and glycine are also stimulated at a similar locus [25, 28, 29] . Pyruvate carboxylation [30] (M. K. Owen and A. P. Ilalestrap, unpublished results) and citrulline synthesis [29] are stimulated secondarily to an increase in the matrix ATI':ADP ratio, and glutaminase is stimulated by an independent means 1-31], It seems likely that these effects are of physiological significance in the liver as those hormones (and valinomycin) that increase the matrix volume also stimulate respiration, fatty acid and glycine oxidation, urea (citrulline) synthesis, glutaminase activity and gluco-
The role of changes in the matrix volume in the hormonal regulation of metabolism Treatment of hepatocytes from starved rats with glucagon, phenylephrine or vasopressin leads to a [32] .
The proposed relationship between the increase in matrix volume and the stimulation of respiration and gluconeogenesis is summarized in Figure 3 and discussed in more detail elsewhere [32-361. It is suggested that the cell endeavours to match its ATP demand with its ATP supply with the minimum perturbation of the cytosolic and mitochondrial ATP:ADP and NADH:NAL)+ ratios. This can be compared with increasing the flow of water into and out of a bath simultaneously, so maintaining the level of water in the bath but with an increased flow through the system. The calcium-mediated increase in 2-oxoglutarate and isocitrate dehydrogenase activities stimulates NADH supply to fuel the respiratory chain and this may be supplemented by activation of fatty acid oxidation. The consequent rise in NADH:NAD+ stimulates cytochrome c reduction and respiration to provide more ATP to drive pyruvate carboxylation and gluconeogenesis. This activation of pyruvate carboxylase is probably mediated by an increase in the 
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matrix ATP:ADP ratio, and may be enhanced by the decrease in glutamate concentration and increase in acetyl-CoA concentration; these metabolites are activators and inhibitors of pyruvate carboxylase, respectively. If only an increase in the NADH:NAD' ratio were responsible for the stimulation of ATP supply, this might have the undesirable consequence of inhibiting gluconeogenesis by reducing cytosolic pyruvate concentrations. The ability of hormones to increase the matrix volume and so activate the respiratory chain circumvents this problem and allows increased rates of respiration in the absence of changes in either the ATP:AI)P or NADH:NAD+ ratios.
In parallel with its effects on gluconeogenesis, the increase in matrix volume may play a vital role in the hormonal stimulation of nitrogen metabolism. Thus mitochondrial citrulline synthesis (and hence urea synthesis) is regulated by the mitochondrial ATP:ADP ratio in much the same manner as pyruvate carboxylation, whereas glycine oxidation and glutamine hydrolysis are both stimulated by a volume-mediated stimulation of glutaminase and the glycine-cleavage enzyme, respectively [25,3 11. 
Implications for the mechanism of action of hypoglycaemic agents
The data described above imply that a hormonal increase in the mitochondrial matrix volume may play an essential role in the regulation of respiration and gluconeogenesis. W e have confirmed that the link between these two processes is very tight by progressively inhibiting the respiratory chain with an inhibitor, 3-( 3,4-dichlorophenyl)-1,l -dimethylurea (DCMU), whose locus of action is similar to that stimulated by an increase in matrix volume [33,36,37]. It was found that gluconeogenesis from i,-lactate was also progressively inhibited and yet this was achieved without major changes in tissue ATP concentrations. Calculation of the flux control coefficient for the control exerted by the respiratory chain over gluconeogenesis gave a value of 0.61 in the absence of hormones, which fell to 0.39 and 0.25 in the presence of glucagon and phenylephrine, respectively [33] . This decrease in flux control coefficient confirms the stimulation of the respiratory chain by these hormones.
W e have investigated the mechanism by which changes in respiratory chain activity can influence the gluconeogenic rate in some detail. These studies involved measurement of tissue metabolite conentrations in order to establish whether DCMU induced a 'crossover' in the metabolite profile of the gluconeogenic pathway, and also determination of the cytosolic and mitochondrial ATP:ADP and NADH:NAD+ ratios and the fluxes through pyruvate kinase and pyruvate carboxylase [33, 36] . Our data suggest that inhibition of the respiratory chain causes a small decrease in mitochondrial and cytosolic ATP concentrations, a modest increase in the ADP concentrations and a very significant decrease in the ATP:ADP ratios, especially in the cytosol [ 361. The decrease in mitochondrial ATP:ADP ratio causes an inhibition of pyruvate carboxylase which may be amplified by a decrease in matrix [acetyl-CoA] as a result of the inhibition of fatty acid oxidation. In addition, tissue [pyruvate] may decrease because the cytosolic NADH:NAD+ ratio rises as a consequence of inhibition of the respiratory chain. In the cytosol, the decrease in the cytosolic ATP:ADP ratio perturbs the equilibrium of phosphoglycerate kinase in favour of 3-phosphoglycerate, and this causes the concentrations of 2-and 3-phosphoglycerate and phosphoenolpyruvate to rise. As [phosphoenolpyruvate] increases, pyruvate kinase is stimulated, futile cycling between pyruvate and phosphoenolpyruvate becomes greater and hence gluconeogenesis is inhibited [36] . This mechanism is illustrated in Figure 3 .
The biguanide hypoglycaemic agents, which are used in the treatment of type 2 diabetes, are thought to inhibit Complex I of the respiratory chain [38] and thus could inhibit hepatic gluconeogenesis by the mechanism described above. This would be of major importance in their hypoglycaemic action [36] . Phenformin treatment of the perfused liver is known to cause changes in the metabolite profile of the gluconeogenic pathway consistent with this mode of action [39] , and we have demonstrated that livers from rats treated with metformin show similar changes (M. R. Owen and A. P. Halestrap, unpublished results) . However, the most commonly prescribed drugs for the treatment of type 2 diabetes are the sulphonylureas such as glibencamide [40] . Although it is clear that these drugs exert a powerful effect on insulin secretion through the inhibition of the ATP-sensitive K + channel of the /3-cell plasma membrane [ 141, it is thought that after prolonged use the major effect of this drug may be extrapancreatic [40-431. Indeed, inhibitory effects of sulphonylureas on hepatic fatty acid oxidation and gluconeogenesis have been described [41, 42] . The discovery that the K+ channel of the mitochondria is also inhibited by these drugs suggests a mechanism by which this might be achieved. Inhibition of K + entry into the mitochondria would allow the K+/H+ antiporter to dominate and so lead to mitochondrial contraction. This would have the effect of inhibiting fatty acid oxidation and gluconeogenesis.
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Changes in mitochondrial volume in other tissues
In the perfused heart and isolated heart mitochondria, changes in [Ca2+] within the physiological range increase neither the matrix [PPi] nor the mitochondrial volume [44] . We have suggested that this may reflect a higher matrix [M$+] in heart mitochondria which overcomes the inhibition of pyrophosphatase by Ca2+. However, respiration and fatty acid oxidation in heart mitochondria are sensitive to changes in matrix volume in a similar manner to that observed in liver mitochondria [27] . Although there is no direct evidence for changes in heart mitochondrial matrix volume in response to hormones or workload, we have argued that it would be advantageous to the cell for such changes to occur [35] . It would enable the heart to increase the rate of /3-oxidation in response to increased workload and so supply the additional acetyl-CoA to fuel the citric acid cycle. In addition, it would also allow the respiratory chain to operate faster without either a decrease in the ATP:ADP ratio, which might impair contraction, or an increase in the NADH:NAD+ ratio, which would increase lactic acid production. Clearly, it is important to establish whether changes in matrix volume do occur in the heart, and if so, by what mechanism.
Evidence for mitochondrial swelling in other tissues, such as brown fat and secretory tissues, comes mainly from morphological studies and is summarized elsewhere [ 1,2].
Effects of changes in cell volume on mitochondrial function
The major emphasis of this colloquium has been the effects of changing cellular volume on metabolism. In liver cells, swelling induced by either hypoosmotic stress or amino acid uptake is associated with a variety of metabolic responses, reviewed in the preceding articles. These responses include a stimulation of respiration, urea synthesis, glutaminase, glycine oxidation and a decrease in the mito- [6] . In general, however, the increase in liver mass was peripheral to the focus of these studies and was not pursued further. W e have recently investigated the early increase in liver mass that occurs upon administration of bacterial endotoxin and found a substantial increase in hepatocyte volume in vivo.
One of the effects of bacterial endotoxin in animals is a contraction of the gastric sphincter, such that little or no food passes into the intestine Abbreviations used: i.p., intraperitoneal; TNF, tumour necrosis factor. 'To whom correspondence should be addressed. even though the stomach may be full. Fed animals are not, therefore, a suitable control for endotoxintreated animals. Our studies were performed on rats that were deprived of food and administered either Escherichia coli endotoxin ( 3 mg/kg) or saline by intraperitoneal ( i p ) injection.
Endotoxin increases hepatic mass
Endotoxin treatment resulted in a marked increase in liver mass. Twenty four hours after a single i.p. injection of endotoxin, the liver mass was -23% larger than in the saline-injected fasted controls and, indeed, was not different from that seen in fed animals (Table 1 ). The increase in liver mass was timeand dose-dependent. A significant increase in hepatic mass was evident as early as 12 h after endotoxin treatment. It was also evident at endotoxin doses as low as 0.3 mg/kg. Most of the increase in mass could be accounted for by a 27% increase in the water content of the liver and there was also a 13% increase in dry mass which may be largely attributed to increased hepatic protein and lipid content. The wet weight:dry weight ratio was significantly increased.
Because many of the metabolic effects of endotoxin are mediated by TNF-a [7] , and because antibodies to TNF-a are known to inhibit liver regeneration after partial hepatectomy [8] , it was of
